The YAP-TEAD protein-protein interaction can be disrupted by small molecules based on a dyhydrobenzofurane scaffold. Herein we report the multi-parameter optimization of this class of inhibitors, resulting in compounds with high cellular activity and a balanced off-target profile. We also demonstrate in vivo efficacy of this class of YAP-TEAD protein-protein inhibitors in mouse tumor models.
BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS
申请人:Novartis AG
公开号:US20210299100A1
公开(公告)日:2021-09-30
The present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof;
a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
[EN] BIFUNCTIONAL DEGRADERS COMPRISING A TEAD BINDER<br/>[FR] AGENTS DE DÉGRADATION BIFONCTIONNELS COMPRENANT UN LIANT DE TEAD
申请人:[en]NOVARTIS AG
公开号:WO2023031801A1
公开(公告)日:2023-03-09
The present disclosure relates to a conjugate comprising a YAP/TAZ-TEAD Protein Protein Interaction Inhibitor (PPII) linked to a Ligase Binder via a linker, or a pharmaceutically acceptable salt thereof, as well as methods of using such conjugates.